Enhertu showed better outcomes in HR-positive, HER2-negative breast cancer, while Trodelvy was more effective in HR-negative, HER2-null tumors when used first. Real-world data from over 4,000 patients ...
– Investigational Long-Acting, Twice-Yearly Treatment Regimen of Lenacapavir and Broadly Neutralizing Antibodies (bNAbs) Meets Primary Endpoint in Phase 2 Study and Gains Breakthrough Therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results